Abstract

The present invention targets a class of compounds able to activate the enzyme SIRT1 in humans by regulating numerous metabolic functions. The appropriately designed compounds could be used in pharmaceutical formulations, preferably in the treatment or prevention of cardiometabolic diseases

Research Institution

Università di Pisa

Numero di pubblicazione

WO2019162911A1

TRL

n.a.

Technologies, Systems, Applications

New drugs development